近年来，针对原发性和继发性肝肿瘤的区域疗法引起了关注，多种治疗方法被追求以控制疾病、缓解症状和延长生存。化学灌注是一种通过肝动脉向肝脏输送高剂量化疗药物的创新方式。在过去的十年中，“孤立性肝脏灌注”（IHP）已从开放手术法发展为一种微创手术，现在称为“化学灌注”（CS）和“经皮肝脏灌注”（PHP）。目前有关CS-PHP的最具有说服力的数据为肝内转移黑色素瘤（UM）患者 - 这是一种罕见但具有较差长期生存率的毁灭性疾病。全球III期研究和几个队列研究提供了有力的证据表明，拥有适当专业知识的机构中的CS-PHP是肝占优势的转移性UM有效的挽救性治疗。在本综述中，我们提供了关于技术、可用的临床数据（包括安全性和有效性）和CS-PHP的潜在适应症的概述。版权所有©2022 Elsevier Ltd。保留所有权利。

Regional therapies for primary and secondary liver tumors have garnered interest in recent years and several types of treatment approaches have been pursued to control disease, palliate symptoms, and extend survival. Chemosaturation is an innovative way to deliver high-dose chemotherapy to the liver via the hepatic artery. Within the last decade, "isolated hepatic perfusion" (IHP) has evolved from an open surgical approach to a minimally invasive procedure, now termed "chemosaturation" (CS) with "percutaneous hepatic perfusion (PHP)". The most conclusive data on CS-PHP is currently available for patients with hepatic metastases from uveal melanoma (UM) - a rare but devastating disease with a poor long-term survival rate. A global phase-3 study and several cohort studies have provided compelling evidence that CS-PHP is an effective salvage treatment for liver-dominant metastatic UM in institutions with appropriate expertise. In this review we provide an overview on the technique, available clinical data, including safety and efficacy, and potential indications for CS-PHP.Copyright © 2022 Elsevier Ltd. All rights reserved.